{"filing":{"accession_number":"0001628280-26-060124","cik":"0001854270","ticker":"SNTI","company_name":"Senti Biosciences Holdings, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-27","primary_document":"snti-20260827.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/snti-20260827.htm"},"events":[{"id":31329,"run_id":28742,"accession_number":"0001628280-26-060124","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Senti Biosciences amended a Securities Purchase Agreement authorizing the issuance and sale of $2.0 million in aggregate principal of Senior Secured Convertible Notes by Midco to NSG BioInnovation Fund, L.P., creating a new direct financial obligation.","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34175,"accession_number":"0001628280-26-060124","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses an amendment to a Securities Purchase Agreement that authorizes the issuance and sale of $2.0 million in aggregate principal of Senior Secured Convertible Notes by Midco to NSG BioInnovation Fund, L.P. This constitutes creation of a new direct financial obligation through debt issuance, which is material to investors assessing the company's capital structure and financing activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:31:03.054658+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31330,"run_id":28742,"accession_number":"0001628280-26-060124","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Senti Biosciences received formal notice from Nasdaq on August 27, 2026 of non-compliance with the Minimum Bid Price Requirement (stock closing below $1.00 for 30 consecutive trading days) and the Stockholders' Equity Requirement (stockholders' deficit of $3.4 million versus $2.5 million minimum), with 180-day compliance periods granted but potential delisting if deficiencies are not cured.","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34176,"accession_number":"0001628280-26-060124","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Senti Biosciences received formal notice from Nasdaq on August 27, 2026 of non-compliance with two critical listing standards: (1) the Minimum Bid Price Requirement (stock closing below $1.00 for 30 consecutive trading days) and (2) the Stockholders' Equity Requirement (stockholders' deficit of $3.4 million versus $2.5 million minimum). The company has been granted compliance periods (180 days for bid price, up to 180 days for equity) but faces potential delisting if it fails to cure these deficiencies. This is a textbook delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:31:03.054658+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34175,"accession_number":"0001628280-26-060124","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses an amendment to a Securities Purchase Agreement that authorizes the issuance and sale of $2.0 million in aggregate principal of Senior Secured Convertible Notes by Midco to NSG BioInnovation Fund, L.P. This constitutes creation of a new direct financial obligation through debt issuance, which is material to investors assessing the company's capital structure and financing activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:31:03.054658+00:00","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-09-02"},{"id":34176,"accession_number":"0001628280-26-060124","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Senti Biosciences received formal notice from Nasdaq on August 27, 2026 of non-compliance with two critical listing standards: (1) the Minimum Bid Price Requirement (stock closing below $1.00 for 30 consecutive trading days) and (2) the Stockholders' Equity Requirement (stockholders' deficit of $3.4 million versus $2.5 million minimum). The company has been granted compliance periods (180 days for bid price, up to 180 days for equity) but faces potential delisting if it fails to cure these deficiencies. This is a textbook delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:31:03.054658+00:00","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-09-02"}]}